Polmed S.A (IFC-49441)

Countries
  • Poland
Geographic location where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Proposed
Stage of the project cycle. Stages vary by development bank and can include: pending, approval, implementation, and closed or completed.
Bank Risk Rating
B
Environmental and social categorization assessed by the development bank as a measure of the planned project’s environmental and social impacts. A higher risk rating may require more due diligence to limit or avoid harm to people and the environment. For example, "A" or "B" are risk categories where "A" represents the highest amount of risk. Results will include projects that specifically recorded a rating, all other projects are marked ‘U’ for "Undisclosed."
Borrower
Polmed SA
A public entity (government or state-owned) provided with funds or financial support to manage and/or implement a project.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Equity
The categories of the bank investment: loan, grant, guarantee, technical assistance, advisory services, equity and fund.
Investment Amount (USD)
$ 34.80 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Currency conversion note:
Bank reported 33
Converted using 2024-11-15 exchange rate.
Project Cost (USD)
$ 185.60 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Currency conversion note:
Bank reported 176
Converted using 2024-11-15 exchange rate.
Bank Documents
Primary Source

Original disclosure @ IFC website

Updated in EWS Mar 16, 2025

Disclosed by Bank Nov 15, 2024

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
If provided by the financial institution, the Early Warning System Team writes a short summary describing the purported development objective of the project and project components. Review the complete project documentation for a detailed description.

According to the Bank’s website, the Project entails a proposed IFC equity investment of up to €33million, for a minority stake in Polmed S.A, a growing Polish private medical services provider. Through this Project, Polmed seeks to expand its portfolio into more specialized services through acquisitions and organic investments.

The most significant expected project-level outcome is to increase access to high-quality specialized services such cancer treatment in Poland, addressing capacity constraints and long waiting times in the public healthcare system. Demand for specialized out-of-hospital oncology services is expected to grow. IFC anticipates that this investment will enhance competitiveness in the private healthcare market by expanding non-invasive treatment options, upskilling medical personnel in innovative cancer surgery, improving healthcare delivery integration, and encouraging adoption of telemedicine and other digital innovations for delivering value-based care. In addition, Polmed presents and demonstrates how private provision can be integrated into public coordinated health system. 

Early Warning System Project Analysis
For a project with severe or irreversible impacts to local community and natural resources, the Early Warning System Team may conduct a thorough analysis regarding its potential impacts to human and environmental rights.

This is a Category B project based on IFC’s 2012 Policy on Environmental and Social Sustainability, as the project involves activities with potential limited adverse environmental or social risks and/or impacts that are a few in number, generally site-specific, largely reversible, and readily addressed through mitigation measures.

Key E&S issues and risks associated with this investment include i. Company’s capacity to establish and maintain corporate and subsidiary level environment and social management systems (ESMS), both for operational and expansion projects (including construction works) in compliance with IFC PS requirements; ii. adequacy of E&S due diligence and risk mitigation and management procedures for the corporate Mergers and Acquisitions (M&A) program and future/planned developments; iii. contractor E&S management; iv. labor and working conditions; v. gender-based violence and harassment (GBVH) and child protection; vi. EPRP, including L&FS management in accordance with local and international fire safety codes; vii. efficiency of water and energy consumption in its operations; viii. management and disposal of solid, and bio-medical/hazardous waste; and ix. stakeholder engagement and external grievance management.

Investment Description
Here you can find a list of individual development financial institutions that finance the project.

IFC’s investment will form part of a €176million fund raise, by Polmed, which will be funded by a combination of equity and debt.

Private Actors Description
A Private Actor is a non-governmental body or entity that is the borrower or client of a development project, which can include corporations, private equity and banks. This describes the private actors and their roles in relation to the project, when private actor information is disclosed or has been further researched.

Polmed S.A. is a Polish private medical services provider established in 1999, and has since grown into a diversified healthcare group offering services in outpatient care, imaging diagnostics, and rehabilitation across multiples cities in Poland. Polmed is owned through two special purposes vehicles that represent the interests of the founders: Romuald Magdon (50%) and Radoslaw Szubert (50%).

Private Actor 1 Private Actor 1 Role Private Actor 1 Sector Relation Private Actor 2 Private Actor 2 Role Private Actor 2 Sector
- - - - Polmed S.A. Client -

Contact Information
This section aims to support the local communities and local CSO to get to know which stakeholders are involved in a project with their roles and responsibilities. If available, there may be a complaint office for the respective bank which operates independently to receive and determine violations in policy and practice. Independent Accountability Mechanisms receive and respond to complaints. Most Independent Accountability Mechanisms offer two functions for addressing complaints: dispute resolution and compliance review.

Polmed S.A.
Mr. Radoslaw Szubert
Chief Executive Officer
+48508162522
r.szubert@polmed.pl
Ul. Os. Mikolaja Kopernika 21 Starogard Gdanski; Pomorskie; Postal Code: 83 200
https://polmed.pl/

ACCESS TO INFORMATION

You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org

How it works

How it works